WARNING! Confusion regarding the generic name of the HER2-targeted drug KADCYLA

On February 22, 2013, the US Food and Drug Administration (FDA)approved KADCYLA with the generic name of ado-trastuzumab emtansine. Unfortunately, some confusion surrounding the drug’s generic name exists. For more information.